ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced its participation at the HC Wainwright 20th Annual Global Investment Conference.
September 11, 2018
· 3 min read